Bionik Laboratories Corp. (OTCMKTS:BNKL) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 disclosure, which was not included in the Form 8-K of Bionik Laboratories Corp. filed on April 25, 2018 (the “Original 8-K”). There are no other modifications or updates to any of the information made in the Original 8-K.
|Item 5.02||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
On April 20, 2018, Eric Dusseux, the Chief Executive Officer and a director of Bionik Laboratories Corp. (the “Company”), was granted a stock option representing a right to acquire 6,000,000 shares of the Company’s common stock. The exercise price of the option is $0.0649, which is equal to the fair market value of the underlying shares determined on the date of grant, and the expiration date will be the 10th anniversary of the date of grant.
In addition, also on April 20, 2018, the Board of Directors of the Company approved the following bonuses to the named executive officers of the Company: (a) to Mr. Dusseux, $136,719, representing a bonus for fiscal 2018; (b) to Michael Prywata, the Company’s Chief Technology Officer and a director, $103,950, representing, collectively, unpaid bonuses for fiscal 2016 and 2017 and a bonus for fiscal 2018; and (c) to Leslie Markow, the Company’s Chief Financial Officer, $116,550, representing, collectively, unpaid bonuses for fiscal 2016 and 2017 and a bonus for fiscal 2018.
|Item 5.07||Submission of Matters to a Vote of Security Holders.|
On March 31, 2018, in accordance with the applicable provisions of the Delaware General Corporation Law (the “DGCL”), the Company’s Board of Directors (the “Board”) unanimously adopted resolutions approving the following proposed actions (each, an “Action” and collectively, the “Actions”):
1.To increase the authorized number of shares of common stock of the Company from 250,000,000 to 500,000,000 (the “Stock Increase”);
2.To authorize a reverse stock split, at a ratio of up to 1:100, of the common stock of the Company (the “Reverse Split”), which will be determined by the Board; and
3.To adopt the Company’s Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, which makes no material changes to the existing Amended and Restated Certificate of Incorporation other than incorporating the amendments described in actions (1) and (2) above.
As of the close of business on April 20, 2018, to the applicable provisions of the DGCL, the Company received a written consent approving the Actions from holders of the common stock and Exchangeable Shares of the Company holding an aggregate of 128,113,372 shares of the common stock of the Company, on an as converted basis, representing approximately 51.32% of the Company’s outstanding shares of voting capital stock.
About Bionik Laboratories Corp. (OTCMKTS:BNKL)
Bionik Laboratories Corp. (Bionik), formerly Drywave Technologies, Inc., is a medical device and robotics company. The Company is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has over three products on the market and approximately three products in various stages of development. The InMotion Systems include the InMotion ARM, InMotion HAND, InMotion Wrist and InMotion ANKLE are designed to provide patent-adaptive therapy in a manner that has been clinically verified to manage neuro-recovery. The Company is also engaged in developing a lower-body exoskeleton, ARKE, which designs to allow paraplegics, as well as other wheelchair users the ability to rehabilitate through walking.